Processa Pharmaceuticals (NASDAQ: PCSA) CAO purchases 1,583 shares and corrects prior Form 4

Rhea-AI Filing Summary

Processa Pharmaceuticals Chief Administrative Officer Wendy Guy reported an open-market purchase of 1,583 shares of common stock at $2.97 per share. After this trade, she directly holds 8,011 shares and is also shown with 333 shares held indirectly through CorLyst, LLC.

The filing also corrects earlier data, noting that a purchase on April 30, 2026 was executed at $2.71 per share instead of $2.69, which reduces that earlier purchase by 13 shares. This adjustment is described as correcting immaterial errors in a prior Form 4.

Insider Trade Summary

Net Buyer: 1,583 shares ($4,702)

Net Buy 2 txns

Insider Guy Wendy

Role Chief Administrative Officer

Bought 1,583 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,583	$2.97	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 8,011 shares (Direct, null); Common Stock — 333 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

1. [object Object]

Key Figures

Open-market purchase: 1,583 shares Purchase price: $2.97 per share Direct holdings after transaction: 8,011 shares +3 more

6 metrics

Open-market purchase 1,583 shares Common Stock bought in open market on May 15, 2026

Purchase price $2.97 per share Price for 1,583-share open-market purchase

Direct holdings after transaction 8,011 shares Common Stock directly owned after May 15, 2026 trade

Indirect holdings 333 shares Common Stock held indirectly through CorLyst, LLC

Corrected prior trade price $2.71 per share Revised price for April 30, 2026 purchase

Share reduction from correction 13 shares Reduction in previously reported April 30, 2026 purchase

Key Terms

open-market purchase, indirect ownership, Form 4, Common Stock

4 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"direct_or_indirect: "I", nature_of_ownership: "By CorLyst, LLC""

Form 4 regulatory

"errors made on the Form 4 filed on May 1, 2026"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guy Wendy

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Administrative Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		P		1,583	A	$2.97	8,011(1)	D
Common Stock								333	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares.

	/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA executive Wendy Guy report?

Wendy Guy reported an open-market purchase of 1,583 Processa Pharmaceuticals common shares at $2.97 per share. Following this transaction, she directly owns 8,011 shares, in addition to an indirect holding of 333 shares through CorLyst, LLC.

What is Wendy Guy’s total direct PCSA shareholding after this Form 4?

After the reported transaction, Wendy Guy directly holds 8,011 Processa Pharmaceuticals common shares. This figure reflects her position following the 1,583-share open-market purchase disclosed, separate from 333 shares held indirectly via CorLyst, LLC.

Does the PCSA Form 4 include any indirect ownership for Wendy Guy?

Yes. The filing lists 333 Processa Pharmaceuticals common shares as indirectly owned by Wendy Guy through CorLyst, LLC. This is in addition to her direct ownership of 8,011 shares reported after the latest open-market purchase.

What correction to a prior PCSA Form 4 does this filing disclose?

The filing states that a prior Form 4 contained immaterial errors for an April 30, 2026 purchase. The corrected price is $2.71 instead of $2.69 per share, reducing the number of shares previously reported for that trade by 13.

Was the PCSA insider transaction a purchase or sale of shares?

The Form 4 shows a purchase. Wendy Guy executed an open-market purchase of 1,583 Processa Pharmaceuticals common shares at $2.97 per share, increasing her direct ownership to 8,011 shares after the transaction.

How many shares did prior PCSA reporting errors affect according to the footnote?

The footnote explains that correcting the April 30, 2026 purchase price from $2.69 to $2.71 per share reduces that earlier purchase by 13 shares. The company characterizes these corrections as immaterial errors in the prior Form 4.